Brief Review on Novel Technology in Breast Cancer Chemotherapy

Authors

  • Puja kumari Shri Bherulal Pharmacy Institute Indore (M.P.) India
  • Sourabh D Jain Shri Bherulal Pharmacy Institute Indore (M.P.) India
  • Jayanti Mukherjee Shri Bherulal Pharmacy Institute Indore (M.P.) India
  • Vimukta Sharma BM College of Pharmaceutical Education and Research Indore (M.P.) India

DOI:

https://doi.org/10.37591/rrjooh.v7i2.382

Abstract

Breast cancer is cancer that develops from breast tissue. Breast cells contain receptors for the two types of hormones estrogen and progesterone. They also contain receptors for a protein called HER2, which induce normal cell growth. Around two out of three women with breast cancer have cells that bear receptors for estrogen and progesterone, and just about 20–30% of breast cancers have too many HER2 receptors. Exploitation chemotherapy to treat triple negative breast cancer is still an efficient option. Triple negative breast cancer can be more assertive and challenging to treat. Also, the cancer is more liable to spread and occur. The treatment model for patients with triple-negative breast cancer (TNBC) is set to go through an impressive transformation, as standard chemotherapeutic approach is formed and novel antibody-drug conjugates (ADCs) are formulated. The selection of therapeutic targets is a critical aspect of antibody-drug conjugate research and development. Several methods of identification of antibody-drug-conjugate molecules are by preformulation study, formulation development, characterization linkers and cytotoxic drugs.

 

Keywords: Breast cancer, cytotoxic, antibody-drug conjugate

Cite this Article

Puja Kumari, Jain Sourabh D, Jayanti Mukherjee et al. Brief Review on Novel Technology in Breast Cancer Chemotherapy. Research & Reviews: Journal of Oncology and Hematology. 2018; 7(2): 22–26p.

Downloads

Published

2018-09-14

Issue

Vol. 7 No. 2 (2018)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.